Observes zanubrutinib use in adults with Waldenström's macroglobulinemia and other lymphomas
Tracks real-world zanubrutinib care and quality of life in adults with these blood cancers.
Plain-language title generated from the registry record
Registry title: Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma
Key facts
- Where
- Salzburg, AustriaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with Waldenström's macroglobulinemia, chronic lymphocytic leukemia, marginal zone lymphoma or follicular lymphoma who are treated with zanubrutinib. It is an observational study.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Waldenström's macroglobulinemia or chronic lymphocytic leukemia: any treatment line. Marginal zone lymphoma: at least 2 treatment lines. Follicular lymphoma: at least 3 treatment lines.
- Earlier treatment
- Marginal zone lymphoma: at least one earlier treatment with an anti-CD20 antibody. The decision to treat with zanubrutinib must be made before joining the study.
Main reasons for not taking part
- Has a contraindication to zanubrutinib listed in the product information (SmPC)
- Takes part in an interventional clinical trial during zanubrutinib treatment
Read by machine on 9 November 2026.
Where in Austria
- Universitätsklinikum Salzburg, Klinik für Innere Medizin IIISalzburg, AustriaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- iOMEDICO AG
- Trial code
- NCT05326308
- Record updated
- 9 September 2026
- Original description
The objective of this NIS is to evaluate medical resource utilization, where data is rare in all cohorts, patient's QoL and effectiveness of zanubrutinib treatment in adult patients with WM, CLL, MZL and FL in a real-world setting.Read full original descriptionShow less
Zanubrutinib (Brukinsa®) in Patients With Waldenström's Macroglobulinemia (WM), Chronic Lymphocytic Leukemia (CLL), Marginal Zone Lymphoma (MZL) and Follicular Lymphoma (FL) - a Prospective Multicenter Observational Cohort Study
The objective of this NIS is to evaluate medical resource utilization, where data is rare in all cohorts, patient's QoL and effectiveness of zanubrutinib treatment in adult patients with WM, CLL, MZL and FL in a real-world setting.
Inclusion: Waldenström's macroglobulinemia (all treatment lines) OR; Chronic lymphocytic leukemia (all treatment lines) OR; Marginal zone lymphoma (≥2 treatment line and at least one anti-CD20 antibody-based previous therapy); Follicular lymphoma (≥3 treatment line); Signed and dated informed consent form; Treatment with zanubrutinib according to current SmPC for WM, CLL and MZL; Treatment with zanubrutinib + obinutuzumab for FL according to current SmPC; Treatment decision before inclusion into this non-interventional study; Age ≥18 years.
Exclusion: Contraindications according to SmPC for patients with WM, CLL, MZL or FL; Participation in an interventional clinical trial during zanubrutinib treatment.